BofAML Adjuvant Ibrance Fails, Putting More Pressure on the $PFE Pipeline
Pfizer announced the phase 3 PALLAS study was stopped for futility,  removing a significant near-term pipeline driver. 
We are maintaining our Neutral but  moving our PO to $38 (from $42)
#ASCO20